XML 17 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]      
Molecular diagnostic testing $ 722.1 $ 705.7 $ 695.5
Pharmaceutical and clinical services 49.3 48.1 27.6
Total revenue 771.4 753.8 723.1
Costs and expenses:      
Cost of molecular diagnostic testing 145.2 132.8 132.8
Cost of pharmaceutical and clinical services 26.0 24.5 14.6
Research and development expense 74.4 70.6 75.5
Selling, general, and administrative expense 476.4 359.1 366.0
Total costs and expenses 722.0 587.0 588.9
Operating income 49.4 166.8 134.2
Other income (expense):      
Interest income 1.2 0.9 0.4
Interest expense (6.0) (0.3) (0.2)
Change in the fair value of contingent consideration 0.8    
Other (2.5) 1.5 0.5
Total other income (expense): (6.5) 2.1 0.7
Income before income tax 42.9 168.9 134.9
Income tax provision 21.3 43.6 54.7
Net income 21.6 125.3 80.2
Net loss attributable to non-controlling interest (0.2)    
Net income attributable to Myriad Genetics, Inc. stockholders $ 21.8 $ 125.3 $ 80.2
Earnings per share:      
Basic $ 0.32 $ 1.79 $ 1.12
Diluted $ 0.32 $ 1.71 $ 1.08
Weighted average shares outstanding:      
Basic 68.3 70.0 71.3
Diluted 68.8 73.4 74.5